Einstein International Journal Organization(EIJO)

Abstract

Cancer remains one of the leading causes of morbidity and mortality worldwide despite significant advancements in diagnosis and treatment. Conventional chemotherapy, although effective in certain cases, is often associated with systemic toxicity, drug resistance, and limited specificity. Recent pharmacological developments have focused on novel anticancer drugs and targeted therapies that selectively act on molecular pathways involved in tumor growth and progression. These therapies include targeted small-molecule inhibitors, monoclonal antibodies, immunotherapies, antibody–drug conjugates, and gene-based approaches. Advances in molecular biology, genomics, and personalized medicine have enabled the identification of specific biomarkers that guide targeted treatment strategies. While these therapies have improved survival outcomes and reduced adverse effects compared to traditional chemotherapy, challenges such as resistance, cost, and accessibility remain. This review highlights recent pharmacological developments in anticancer drugs, mechanisms of targeted therapies, clinical advancements, and future perspectives in precision oncology.

Keywords: Anticancer drugs, targeted therapy, immunotherapy, monoclonal antibodies, precision medicine, pharmacological advances, cancer treatment.

1. Patel, A. A. (2024). Recent advances in immunotherapy in cancer treatment. Cellular and Molecular Biology, 70(5), 89–99.
2. Ghemrawi, R., Abuamer, L., Kremesh, S., Hussien, G., Ahmed, R., Mousa, W., & Khoder, G. (2024). Revolutionizing cancer treatment: Recent advances in immunotherapy. Biomedicines, 12(9), 2158.
3. Ma, S., Hu, R., Xue, X., Qu, M., & Sun, G. (2025). Novel therapeutic strategies for non-small cell lung cancer: Combination therapies with immune checkpoint inhibitors. Oncology Letters, 30(3), 424.
4. Zhang, Y., Li, Y., Fu, Q., Han, Z., Wang, D., Shinge, S. A. U., Muluh, T. A., & Lu, X. (2023). Combined immunotherapy and targeted therapies for cancer treatment: Recent advances and future perspectives. Current Cancer Drug Targets, 23(4), 251–264.
5. Liu, Y., Chen, J., Xu, Y., & Sun, Q. (2022). Novel insight into the role of immunotherapy in gastrointestinal cancer. Molecular and Clinical Oncology, 17(4), 157.
6. Abdeldjouad, F. Z., Brahami, M., & Sabri, M. (2024). Evaluating artificial intelligence in predicting adverse drug reactions among cancer patients: A systematic review and meta-analysis. arXiv Preprint.
7. Ahmad, U., Harun, S., Diagne, M. M., Abdullah, S., Yusoff, K., & Veerakumarasivam, A. (2025). Oncolytic mechanisms and immunotherapeutic potential of Newcastle disease virus in cancer therapy. arXiv Preprint.
8. Kumar, M. (2023). Precision oncology, signaling pathways reprogramming and targeted therapy: A holistic approach to molecular cancer therapeutics. arXiv Preprint.
9. Withrow, A. D. M., Blythe, S. M., Burton, J. T., & Evett, C. G. (2024). Advanced targeted drug delivery for colon cancer using hydroxyapatite nanoparticles. arXiv Preprint.
10. Siegel, R. L., Miller, K. D., Wagle, N. S., & Jemal, A. (2023). Cancer statistics, 2023. CA: A Cancer Journal for Clinicians, 73(1), 17–48.
11. Ferrara, R., Mezquita, L., Auclin, E., & Besse, B. (2023). Immunotherapy resistance in cancer: Mechanisms and strategies. Nature Reviews Clinical Oncology.
12. Doroshow, D. B., Sanmamed, M. F., Hastings, K., Politi, K., Rimm, D. L., Chen, L., Melero, I., Schalper, K. A., & Herbst, R. S. (2023). Immunotherapy in non-small cell lung cancer. Journal of Clinical Oncology.
13. Schmid, P., Adams, S., Rugo, H. S., et al. (2022). Atezolizumab and chemotherapy in advanced triple-negative breast cancer. New England Journal of Medicine.
14. Swanton, C., Govindan, R. (2023). Clinical implications of tumor heterogeneity. Lancet Oncology.
15. Hodi, F. S., Chiarion-Sileni, V., Gonzalez, R., et al. (2022). Long-term survival in advanced melanoma with nivolumab. New England Journal of Medicine.
16. Lu, R. M., Hwang, Y. C., Liu, I. J., et al. (2022). Development of therapeutic antibodies for cancer therapy. Journal of Biomedical Science.
17. Beck, A., Goetsch, L., Dumontet, C., & Corvaïa, N. (2022). Strategies and challenges for antibody–drug conjugates. Nature Reviews Drug Discovery.
18. Tsimberidou, A. M., Fountzilas, E., Nikanjam, M., & Kurzrock, R. (2022). Review of precision cancer medicine. Nature Reviews Clinical Oncology.
19. Haslam, A., & Prasad, V. (2023). Estimation of survival benefit of cancer drugs. JAMA Network Open.
20. Adams, S., Gatti-Mays, M. E., Kalinsky, K., et al. (2023). Current landscape of immunotherapy in breast cancer. JAMA Oncology.
21. Hanna, N. H., Schneider, B. J., Temin, S., et al. (2023). Therapy for stage IV non-small cell lung cancer. Journal of Clinical Oncology.
22. Sharma, P., Siddiqui, B. A., Anandhan, S., Yadav, S. S., Subudhi, S. K., Gao, J., Goswami, S., & Allison, J. P. (2023). The next decade of immune checkpoint therapy. Cancer Discovery.